144 related articles for article (PubMed ID: 22289971)
1. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy.
Ayzenberg I; Lukas C; Trampe N; Gold R; Hellwig K
J Neurol; 2012 Aug; 259(8):1732-3. PubMed ID: 22289971
[No Abstract] [Full Text] [Related]
2. Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical?
Arnaud FX; Hissene A; Métivier D; Dutasta F; Berets O; N'guema B; A'teriitéhau C; Baccialone J; Potet J
J Neuroradiol; 2012 Oct; 39(4):267-70. PubMed ID: 22341620
[TBL] [Abstract][Full Text] [Related]
3. The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?
Phan-Ba R; Belachew S; Outteryck O; Moonen G; Sindic C; Vokaer M; Vermersch P
Neurology; 2012 Sep; 79(10):1067-9. PubMed ID: 22914844
[No Abstract] [Full Text] [Related]
4. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab-induced PML: can the beast be tamed?
Hohlfeld R
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1065. PubMed ID: 23475818
[No Abstract] [Full Text] [Related]
6. Lessons from the clinic: a case of natalizumab-associated PML.
Clifford DB
Neurology; 2011 Feb; 76(6):574. PubMed ID: 21300972
[No Abstract] [Full Text] [Related]
7. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Hoepner R; Ahlbrecht J; Faissner S; Schneider R; Dahlhaus S; Adams O; Raab P; Lukas C; Chan A; Stangel M; Gold R
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1177-8. PubMed ID: 24700881
[No Abstract] [Full Text] [Related]
8. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
9. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
Wattjes MP; Verhoeff L; Zentjens W; Killestein J; van Munster ET; Barkhof F; van Eijk JJ
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1176-7. PubMed ID: 23695498
[No Abstract] [Full Text] [Related]
10. Progressive multifocal leukoencephalopathy and natalizumab.
Hellwig K; Gold R
J Neurol; 2011 Nov; 258(11):1920-8. PubMed ID: 21647730
[TBL] [Abstract][Full Text] [Related]
11. A case of natalizumab-associated progressive multifocal leukoencephalopathy-role for advanced MRI?
Berghoff M; Dassinger B; Iwinska-Zelder J; Giraldo M; Bilgin S; Kaps M; Gizewski ER
Clin Neuroradiol; 2014 Jun; 24(2):173-6. PubMed ID: 23532437
[No Abstract] [Full Text] [Related]
12. Natalizumab-induced progressive multifocal leukoencephalopathy.
Thaker AA; Schmitt SE; Pollard JR; Dubroff JG
Clin Nucl Med; 2014 Jul; 39(7):e365-6. PubMed ID: 24152618
[TBL] [Abstract][Full Text] [Related]
13. Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Hodel J; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Pruvo JP; Vermersch P; Leclerc X
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2296-302. PubMed ID: 26316568
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Décard BF; Haghikia A; Tönnes C; Thöne J; Lukas C; Chan A; Gold R
Mult Scler; 2013 Feb; 19(2):249-51. PubMed ID: 22596228
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
Wattjes MP; Barkhof F
Curr Opin Neurol; 2014 Jun; 27(3):260-70. PubMed ID: 24739400
[TBL] [Abstract][Full Text] [Related]
16. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Landy DC; Hecht EM
Clin Neuropharmacol; 2014; 37(2):45-51. PubMed ID: 24614671
[TBL] [Abstract][Full Text] [Related]
17. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
[TBL] [Abstract][Full Text] [Related]
19. The manifold faces of PML and the challenge of diagnosis.
Berger JR; Clifford DB
Neurology; 2011 Dec; 77(23):2006-7. PubMed ID: 22076547
[No Abstract] [Full Text] [Related]
20. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
Rossi F; Newsome SD; Viscidi R
Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]